France · Delayed Price · Currency is EUR Ipsen Earnings Call Transcripts
Fiscal Year 2026
-
Q3 sales rose 26.7% at constant exchange rates, and strong core-portfolio momentum drove higher FY 2026 sales and margin guidance. Somatuline generics and launch investment are expected to pressure future margins, while several late-stage pipeline catalysts approach.
-
H1 2026 saw robust sales and margin growth, driven by all therapeutic areas and supported by three positive phase III readouts and two strategic acquisitions. Upgraded guidance reflects strong momentum, with continued investment in R&D and commercial launches.
-
Q1 2026 saw 22.6% sales growth, driven by all therapeutic areas, with strong gains in rare disease and neuroscience. Guidance for 2026 is reaffirmed, but caution remains due to anticipated generic competition for Somatuline in H2.
Fiscal Year 2025
-
Double-digit sales and profit growth were achieved, with strong performance across all therapeutic areas and a robust pipeline. 2026 guidance anticipates continued double-digit growth, limited generic competition for Somatuline, and significant R&D and business development milestones.
-
Double-digit sales and margin growth led to upgraded 2025 guidance, with rare disease and neuroscience segments driving strong performance. Pipeline advances include the ImCheck acquisition and positive IPN10200 data, while Somatuline faces gradual generic erosion in 2026.
-
H1 2025 saw 11.4% sales growth, margin expansion, and strong cash flow, prompting upgraded full-year guidance. Pipeline advances and new approvals, especially in oncology and rare disease, support continued growth, while Somatuline faces generic headwinds.
-
Q1 2025 sales rose 11.6% with strong growth across all segments, led by Bylvay and IQIRVO launches. Guidance for 2025 is reaffirmed, with Somatuline facing accelerated generic erosion and key pipeline milestones expected.
Fiscal Year 2024
-
Sales grew 9.9% in 2024, with strong gains in oncology, rare disease, and neuroscience. 2025 guidance targets over 5% sales growth and a core margin above 30%, despite Somatuline generic erosion. Pipeline momentum and EUR 2.3B for innovation support future growth.
-
Sales grew 9.2% year-to-date and 8.6% in Q3, led by Dysport, Bylvay, and new launches Iqirvo and Onivyde. Full-year guidance was raised to over 8% sales growth and above 31% margin, with strong pipeline progress and positive physician feedback on new products.
-
Sales grew 9.5% in H1 2024, driven by strong launches and robust pipeline progress. Upgraded guidance expects over 7% sales growth for the year, with Somatuline erosion offset by new products. Free cash flow and profitability remain strong.